In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.
The ACR’s delegation to the American Medical Association House of Delegates is seeking ACR members who may be interested in serving as representatives to the Young Physician Section.

Bryn Nelson, PhD |
Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…
Changes announced April 1 will cut 10,000 positions at the U.S. Department of Health & Human Services and consolidate many department functions. The ACR is monitoring how these changes may impact regulatory issues of concern to ACR members.

A new study questions whether acetaminophen is a risk-free pain reliever for patients aged 65 and older, including those with osteoarthritis (OA). Although acetaminophen is often touted as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, a population-based cohort study found it carried an increased risk of peptic ulcers, bleeding and other side…
This May, more than 120 ACR leaders, fellows and patients with rheumatic disease will converge in Washington, D.C., to lobby Congress on issues including protecting Medicare and Medicaid, National Institutes of Health research funding and pharmacy benefit manager reform.

Catherine Kolonko |
‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…
Joseph Cantrell, JD |
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
Colby Tiner, MA |
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.